Myeloproliferative Disorders: all 640 studies

Page 3 of 7. Open to participants first (111), then studies with results posted, then the rest; newest registration first within each.

• Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell TransplantationTerminatedNCT01116232Phase 2Results posted
• Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative NeoplasmCompletedNCT01101880Phase 2Results posted
• Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01093586Phase 2Results posted
• Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesTerminatedNCT01076270Not applicableResults posted
• Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical DonorTerminatedNCT00967343Phase 2/3Results posted
• COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I TrialCompletedNCT00952289Phase 3Results posted
• Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure DisordersCompletedNCT00856388Not applicableResults posted
• Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic CancerTerminatedNCT00827099Phase 2Results posted
• Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic CancerTerminatedNCT00818961Phase 2Results posted
• Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell TransplantCompletedNCT00795769Phase 2Results posted
• Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological CancerCompletedNCT00787761Phase 2Results posted
• Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure DisorderCompletedNCT00755040Phase 3Results posted
• Methadone, Morphine, or Oxycodone in Treating Pain in Patients With CancerTerminatedNCT00726830Not applicableResults posted
• Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential ThrombocythemiaTerminatedNCT00726232Phase 2Results posted
• Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic CancerCompletedNCT00723099Phase 2Results posted
• Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other DiseaseTerminatedNCT00719849Phase 2Results posted
• American Ginseng in Treating Patients With Fatigue Caused by CancerCompletedNCT00719563Phase 3Results posted
• Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell TransplantCompletedNCT00691015Phase 2Results posted
• T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic MalignanciesCompletedNCT00683046Phase 2Results posted
• CC-4047 in Treating Patients With MyelofibrosisCompletedNCT00669578Phase 1/2Results posted
• Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer PainCompletedNCT00666211Phase 3Results posted
• Low-Dose Decitabine in Treating Patients With Symptomatic MyelofibrosisTerminatedNCT00630994Phase 2Results posted
• Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic CancerCompletedNCT00611351Phase 2Results posted
• Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative DiseasesCompletedNCT00606307Phase 2Results posted
• T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other DiseasesTerminatedNCT00589602Phase 2Results posted
• Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological CancerCompletedNCT00589563Phase 2Results posted
• Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid LeukemiaCompletedNCT00588809Phase 2Results posted
• Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial CarcinomaCompletedNCT00588666Phase 2Results posted
• Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)TerminatedNCT00579111Phase 1/2Results posted
• T-Reg Cell Kinetics, Stem Cell Transplant, REGALETerminatedNCT00578539Not applicableResults posted
• Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic CancerTerminatedNCT00555048Phase 1/2Results posted
• Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other DisordersActive, not recruitingNCT00544115Phase 2Results posted
• Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHDCompletedNCT00539695Phase 2Results posted
• Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow TransplantCompletedNCT00530218Phase 2Results posted
• Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With CancerCompletedNCT00516503Phase 3Results posted
• Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell TransplantCompletedNCT00513474Phase 1Results posted
• Aflibercept in Treating Patients With Myelodysplastic SyndromesTerminatedNCT00509249Phase 2Results posted
• MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic LeukemiaCompletedNCT00462605Phase 2Results posted
• Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other DiseasesCompletedNCT00453206Not applicableResults posted
• Pegasys® in Patients With Myeloproliferative DiseasesCompletedNCT00452023Phase 2Results posted
• Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based RegimenCompletedNCT00448357Phase 1/2Results posted
• Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other DiseaseCompletedNCT00448201Phase 2Results posted
• Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedNCT00425477Phase 2Results posted
• Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell TransplantCompletedNCT00408681Not applicableResults posted
• Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative DisordersCompletedNCT00397813Phase 2Results posted
• Azacitidine in Treating Patients With MyelofibrosisTerminatedNCT00381693Phase 2Results posted
• 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00381550Phase 2Results posted
• Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)CompletedNCT00361140Phase 4Results posted
• Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous LeukemiaCompletedNCT00322101Phase 3Results posted
• Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood TransplantCompletedNCT00305682Phase 2Results posted
• Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic CancerTerminatedNCT00295880Phase 1/2Results posted
• Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell TransplantCompletedNCT00293384Not applicableResults posted
• Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic CancerTerminatedNCT00281879Phase 2Results posted
• Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic CancerTerminatedNCT00255684Not applicableResults posted
• Imatinib Mesylate in Treating Patients With MyelofibrosisTerminatedNCT00245128Phase 2Results posted
• Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00245037Phase 1/2Results posted
• Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic CancerCompletedNCT00134017Phase 2Results posted
• Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic CancerCompletedNCT00134004Phase 2Results posted
• Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00118352Phase 2Results posted
• Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without CancerCompletedNCT00112593Not applicableResults posted
• Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00105001Phase 2Results posted
• Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell TransplantCompletedNCT00096161Phase 2Results posted
• Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)CompletedNCT00075816Phase 3Results posted
• Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic CancerCompletedNCT00075478Phase 3Results posted
• Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph CancersTerminatedNCT00074490Phase 2Results posted
• Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic SyndromesCompletedNCT00072475Phase 2Results posted
• Donor Stem Cell Transplant in Treating Patients With Hematologic CancerCompletedNCT00054327Phase 2Results posted
• NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/DisordersCompletedNCT00053989Phase 2Results posted
• Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic SyndromesCompletedNCT00045305Phase 2Results posted
• Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological MalignanciesCompletedNCT00040846Phase 2Results posted
• Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic CancerCompletedNCT00027560Phase 2Results posted
• Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid CancerCompletedNCT00014495Phase 1/2Results posted
• Specialized Blood Cell Transplants for Cancers of the Blood and Bone MarrowCompletedNCT00003838Phase 2Results posted
• Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic CancerCompletedNCT00003816Phase 2/3Results posted
• Pacritinib With Aza for Upfront Myelodysplastic SyndromeWithdrawnNCT07387354Phase 1/2
• Autoantibodies Against Type I Interferon in Patients Affected With Ph-negative Myeloproliferative Neoplasms (MPN-IFN Study)Active, not recruitingNCT07204366
• Establishment of a Strategy for Preventing Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation by Exploring Immune Mechanisms of Regulatory and Effector T CellsCompletedNCT07150468
• Evaluation of the Prognostic Impact of Decreased Serum beta2 Microglobulin in the First Year of Follow-up of Myeloproliferative Neoplasia (PRODIGE)Active, not recruitingNCT06553638
• Characterization of Myeloproliferative Neoplasia With a Mutated IDH, SRSF2 or SF3B1 Allele (CARPEDIEM)Status unknownNCT06481345
• Diagnostic Characterization and Evolution of "Triple Negative" Thrombocytosis (CASTETTE)Active, not recruitingNCT06481332
• Observatory of Patients With MyeloProliferative Neoplasm Treated With Anti-inflammatory ImmunotherapyActive, not recruitingNCT06476535
• P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 RiskActive, not recruitingNCT06468033Phase 3
• Ultrasound Examination for Spleen Volume Evaluation in Myeloproliferative NeoplasmsCompletedNCT06371573
• A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative NeoplasmsActive, not recruitingNCT06313593Phase 1
• Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia VeraWithdrawnNCT06290765Phase 4
• Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative NeoplasmsWithdrawnNCT06284460Phase 1/2
• Functional Characterization of Thrombopoietin/cMPL Receptor Mutations in Myeloproliferative NeoplasiaActive, not recruitingNCT06246006
• PREVALENCE STUDY OF PNH CLONES IN PATIENTS WITH NEOPLASIESCompletedNCT06159816
• Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid NeoplasmsActive, not recruitingNCT06034470Phase 1
• HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD ProphylaxisActive, not recruitingNCT06001385Phase 2
• Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS StudyCompletedNCT05972577Not applicable
• A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmsActive, not recruitingNCT05936359Phase 1
• Cord Blood Transplant in Adults With Blood CancersActive, not recruitingNCT05884333Phase 2
• Epidemiological and Clinical-pathological Factors of Philadelphia-negative Myeloproliferative Neoplasms in EcuadorCompletedNCT05825326
• Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older PatientsActive, not recruitingNCT05823571Phase 1
• Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN NeoplasmsActive, not recruitingNCT05732961Phase 2
• Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative NeoplasmActive, not recruitingNCT05600894Phase 2
• Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)TerminatedNCT05524857Phase 1
• A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ETActive, not recruitingNCT05482971Phase 2
• Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid NeoplasmsActive, not recruitingNCT05455294Phase 1

← Myeloproliferative Disorders overview